FDA lifts par­tial hold on Ku­ra's Phase Ib AML pro­gram as biotech re­dou­bles mit­i­ga­tion ef­forts

Ku­ra On­col­o­gy is clear to re­sume stud­ies for its ear­ly-stage leukemia pro­gram af­ter the FDA lift­ed a clin­i­cal hold Thurs­day af­ter­noon.

Reg­u­la­tors had placed the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER